113 results on '"Mayo-de-las-Casas, Clara"'
Search Results
2. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
3. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
4. Correction to: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
5. Adaptive Resistance Mechanisms in EGFR Mutant NSCLC
6. DetectingALK,ROS1andRETfusions and theMETΔex14splicing variant in liquid biopsies of non‐small cell lung cancer patients using RNA ‐based techniques
7. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
8. Supplementary Figures 1 - 10, Tables 1 - 11 from Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
9. Fluorescence In Situ Hybridization (FISH) for the Characterization and Monitoring of Primary Cultures from Human Tumors
10. Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques.
11. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
12. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
13. Abstract 1424: Prospective validation of a mRNA signature in plasma for the diagnosis of early stage lung cancer
14. Abstract 1610: Primary cultures from malignant pleural effusions and ascites for drug screening in personalized therapy
15. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
16. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
17. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
18. Abstract 2606: A nCounter-Based mRNA signature in plasma associates with localized non-small cell lung cancer
19. Analysis of Copy Number Variations in Solid Tumors Using a Next Generation Sequencing Custom Panel
20. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
21. Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform
22. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
23. Multiplexed detection of predictive fusions and splicing variants in RNA from lung cancer tissue samples using a hybridization-based platform: narrative review
24. Abstract 929: Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients
25. Abstract B03: Urine cell-free DNA (cfDNA) concentration and stability test for future clinical use
26. Annotating the next generation sequencing report
27. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof‐of‐concept study
28. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
29. Abstract 1384: nCounter for detection of clinically relevant alterations in liquid biopsies of solid tumor patients
30. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report
31. Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib
32. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens
33. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens
34. Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.
35. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy
36. Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
37. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
38. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
39. Evolution and Clinical Impact of EGFRMutations in Circulating Free DNA in the BELIEF Trial
40. Liquid Biopsy in Non-Small Cell Lung Cancer
41. Abstract 3964: Large scale noninvasive screening of EGFR mutations in advanced NSCLC patients: the Identify platform experience
42. EGFR mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.
43. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors
44. Serial mutational analysis to monitor disease evolution in blood from advanced non small cell lung cancer (NSCLC) patients (p).
45. Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
46. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
47. Control de la diferenciación celular in vitro en células HT-29 de cáncer colorectal
48. Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
49. Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).
50. Early evolution of BRAFV600status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.